The C allele of the rs741301 polymorphism in the ELMO1 gene is associated with increased risk of diabetic retinopathy in patients with type 2 diabetes mellitus
Luciane Moretto, Letícia de Almeida Brondani, Eliandra Girardi, Anna Carolina Meireles Vieira, Natália Emerim Lemos, Marilu Fiegenbaum, Luís Henrique Canani, Daisy Crispim, Cristine Dieter

TL;DR
A genetic variant in the ELMO1 gene is linked to a higher risk of diabetic retinopathy in people with type 2 diabetes in Southern Brazil.
Contribution
The study identifies a novel association between the ELMO1 rs741301 C allele and increased DR risk in T2DM patients.
Findings
The C/C genotype of rs741301 was more frequent in DR cases than controls.
The C allele was associated with increased DR risk after adjusting for covariables.
The association remained significant in dominant and additive inheritance models.
Abstract
To investigate the association of the rs741301 polymorphism in the ELMO1 gene with diabetic retinopathy (DR) in patients with type 2 diabetes mellitus (T2DM). This study analyzed 350 patients withT2DM and DR (cases) and 234 patients withT2DM without this complication but with more than 10 years of diabetes mellitus (DM) (controls). DR was diagnosed by indirect fundoscopy. Genotyping was performed by allelic discrimination real-time PCR. The frequency of the C/C genotype of the rs741301 polymorphism in the ELMO1 gene was 26.9% in cases and 17.9% in controls (P = 0.011). After adjustment for covariables, the C/C genotype was associated with an increased risk of DR [odds ratio (OR) = 1.805, 95%CI 1.101–2.961; P = 0.019]. This association remained significant in dominant and additive inheritance models after adjustment for the same variables [OR = 1.597, 95%CI 1.089-2.343; P = 0.017; and…
Genes, proteins, chemicals, diseases, species, mutations and cell lines named across the full text — each resolved to its canonical identifier and authoritative record.
| Characteristics | Controls (n = 234) | Cases with DR (n = 350) | P* |
|---|---|---|---|
| Age (years) | 69.8 ± 10.5 | 66.2 ± 10.2 | <0.0001 |
| DM duration (years) | 49.3 ± 10.5 | 45.3 ± 10.6 | <0.0001 |
| Gender (% males) | 40.3 | 55.1 | 0.001 |
| HbA1c (%) | 7.3 ± 1.9 | 7.5 ± 1.8 | 0.111 |
| BMI (kg/m2) | 28.6 ± 5.2 | 28.2 ± 5.1 | 0.310 |
| Arterial hypertension (%) | 84.5 | 90.3 | 0.061 |
| Triglycerides (mg/dL) | 142.0 (106.0-213.0) | 145.0 (101.0-208.0) | 0.881 |
| Total cholesterol (mg/dL) | 191.9 ± 53.9 | 193.6 ± 51.3 | 0.715 |
| LDL cholesterol (mg/dL) | 109.2 ± 46.5 | 115.6 ± 45.3 | 0.140 |
| HDL cholesterol (mg/dL) | 46.5 ± 12.4 | 13.7 ± 12.0 | 0.008 |
| DKD (%) | 53.6 | 78.0 | <0.0001 |
| ELMO1 rs741301 SNP | Controls (n = 234) | Cases (n = 350) | Unadjusted P* | Adjusted OR (95% IC)/P† |
|---|---|---|---|---|
| Genotype | ||||
| T/T | 95 (40.6) | 107 (30.5) | 0.011 | 1 |
| T/C | 97 (41.5) | 149 (42.6) | 1.496 (0.987-2.269)/0.058 | |
| C/C | 42 (17.9) | 94 (26.9) | 1.805 (1.101-2.961)/0.019 | |
| Allele | ||||
| T | 0.61 | 0.52 | 0.001 | |
| C | 0.39 | 0.48 | ||
| Recessive model | ||||
| T/T + T/C | 192 (82.1) | 256 (73.1) | 0.017 | 1 |
| C/C | 42 (17.9) | 94 (26.9) | 1.443 (0.931-2.237)/0.101 | |
| Additive model | ||||
| T/T | 95 (69.3) | 107 (53.2) | 0.004 | 1 |
| C/C | 42 (30.7) | 94 (46.8) | 1.818 (1.099-3.007)/0.020 | |
| Dominant model | ||||
| T/T | 95 (40.6) | 107 (30.6) | 0.016 | 1 |
| T/C + C/C | 139 (59.4) | 243 (69.4) | 1.597 (1.089-2.343)/0.017 | |
- —CNPq
- —Fipe
- —Fapergs
Peer Reviews
No public reviews on file for this paper yet. If you reviewed it on a platform where reviews are public (OpenReview, ICLR, NeurIPS, ICML), you can paste yours below so the community can read it here.
Videos
No videos yet. Explain this paper in a talk, walkthrough, or lecture? Add one.
Taxonomy
TopicsApelin-related biomedical research · Hormonal Regulation and Hypertension · Diabetes and associated disorders
INTRODUCTION
Diabetic retinopathy (DR) is a major microvascular complication of diabetes mellitus (DM), affecting approximately one-third of patients with DM (1. Despite being insidious and asymptomatic in its early stages, DR can advance over the years, potentially leading to irreversible vision impairment (^1,2^). The development and progression of DR are influenced by a complex interplay of clinical, environmental, and genetic factors (2.
Among the genetic factors, several single nucleotide polymorphisms (SNPs) in different genes have been identified as associated with DR [reviewed in (^3^)]. In this context, SNPs in the TGFB1 (^4^), TIE2 (^5^), ANGPT1 (^5^), and BDKRB1 (^6^) genes were previously reported to be associated with protection against DR, while SNPs in ANGPT2 (^7^), VEGFA (^8^), IL10 (^9^), TNF (^10^), UCP1 (^11^), and UPC2 (^12^) genes were associated with an increased risk of DR. However, these findings provide only partial insight into the DR development. Hence, identifying new genetic factors linked to this complication could advance our understanding of its progression.
The engulfment and cell motility 1 (ELMO1) gene encodes a member of engulfment and cell motility protein family, which plays a role in various processes such as apoptotic cell phagocytosis (^13^), fibroblast migration (^14^), cytoskeleton reorganization (^15^), and lymphocyte infiltration (^16^) by interacting with the Dock180 protein. The rs741301 SNP in the ELMO1 gene has been associated with increased risk of diabetic kidney disease (DKD) in different populations (^17,18,19,20,21,22,23^). ELMO1 appears to contribute to renal damage by being involved in angiogenesis and in the accumulation of oxidative stress (^24,25^). Since angiogenesis and increased oxidative stress are common pathways in DKD and DR (^26^), ELMO1 could also be considered a potential candidate gene for DR. Therefore, this study aimed to investigate the association between the rs741301 SNP in the ELMO1 and DR in patients with type 2 DM (T2DM) from a Southern Brazilian population, given the lack of studies examining the role of ELMO1 in the DR pathogenesis.
MATERIALS AND METHODS
DR patients, phenotype measurements, and laboratory analyses
This case-control study was designed following STROBE and STREGA guidelines for reporting genetic association studies (^27,28^). The study population consisted of 584 type 2 DM (T2DM) patients, divided into 350 cases with DR and 234 controls without this complication. Only patients diagnosed with DM for at least 10 years were included in the control group. All participants were recruited from the outpatient clinic at the Hospital de Clínicas de Porto Alegre (Rio Grande do Sul, Brazil) from January 2005 to December 2013 (^12,29^). The research protocol was approved by the Ethics Committee in Research at Hospital de Clínicas de Porto Alegre, and all subjects provided written informed consent prior to the inclusion in the study.
Patients were diagnosed with T2DM according to the American Diabetes Association guidelines (30. DR was assessed by an experienced ophthalmologist using indirect fundoscopy through dilated pupils. DR was classified as “absent DR” (no fundus abnormalities), “non-proliferative DR” (NPDR; presence of microaneurysms, intraretinal hemorrhages, and hard exudates), or “proliferative DR” (PDR; newly formed blood vessels and/or growth of fibrous tissue into the vitreous cavity). DR classification was based on the most severely affected eye, according to the Global Diabetic Retinopathy Group scale (31. Patients without available DNA samples or with insufficient information for DR classification were excluded from this study.
A standard questionnaire was used to collect information on age, age at DM diagnosis, type and duration of DM, and drug treatment. Additionally, all patients underwent comprehensive physical and laboratory evaluations, as previously reported by our group (^12,29^). Ethnicity was defined based on self- classification, and only white subjects were included in the study. Serum and plasma samples were collected for laboratory analyses after 12h of fasting. Glucose levels were determined using the glucose oxidase method. Glycated hemoglobin (HbA1c) levels were measured by various methods, with results traceable to the Diabetes Control and Complications Trial (DCCT) method with offline calibration or using a conversion formulae (^32^).
Genotyping
Total DNA was extracted from peripheral blood samples using a standardized technique. The ELMO1 rs741301 SNP were genotyped using TaqMan SNP Genotyping Assays 20X (Thermo Fisher Scientific, Foster City, CA, USA; Assay ID: C_2672066_1_). Real-Time PCR reactions were performed in 384-well plates with a total volume of 5 µL, containing 2 ng of DNA, TaqMan Genotyping Master Mix 1X (Thermo Fisher Scientific), and TaqMan Genotyping Assay 1X. PCR reactions were conducted in a ViiA7 Real-Time PCR System (Thermo Fisher Scientific).
Statistical analyses
Genotype and allele frequencies of the ELMO1 rs741301 SNP were estimated by direct allele count- ing, and the Hardy-Weinberg Equilibrium (HWE) was tested using the chi-square (χ2) test. Allele and geno- type frequencies were compared between groups of subjects using χ2 tests. Moreover, genotypes were com- pared between groups of patients considering different inheritance models, categorized as previously suggested in: recessive (0: TT-TC vs. 1: CC), dominant (0: TT vs. 1: TC-CC), and additive (0: TT vs. 1: C/C) (^33^).
Normal distributions of quantitative clinical and laboratory variables were assessed using Kolmogorov- Smirnov and Shapiro-Wilk tests. Variables with normal distribution are presented as mean ± SD, while those with skewed distribution were log-transformed before analysis and are shown as median (25th-75th percentile values). Categorical data are presented as percentage. Clinical and laboratory characteristics were compared between case and control groups using Student’s t-test or χ2 tests.
The magnitude of association between the ELMO1 rs741301 SNP and DR was estimated using odds ratios (OR) with 95% confidence intervals (CI). Multivariate logistic regression analyses were conducted to evaluate the independent association of the SNP of interest with DR, adjusting for possible confounding factors. Statistical analyses were performed using SPSS 18.0 software (SPSS, Chicago, IL), and P values < 0.05 were considered significant.
RESULTS
Sample description
The main characteristics of T2DM patients with and without DR are shown in Table 1. The mean age was higher in the control group compared to the case group (69.8 ± 10.5 vs. 66.2 ± 10.2; P < 0.0001). The proportion of males was higher in the case group than in the control group (55.1% vs. 40.3%; P = 0.001). As expected, the prevalence of DKD was higher in cases with DR compared to controls (78.0% vs. 53.6%; P < 0.0001).
Table 1: Clinical and laboratory characteristics of T2DM patients categorized according to the presence of DR
Genotype and allele frequencies
Table 2 describes allele and genotype frequencies of the rs741301 SNP in the ELMO1 gene in both case and control groups. Genotype distributions of the rs741301 SNP were consistent with the HWE in the control group (P ≥ 0.05). The frequency of the C/C genotype was higher in T2DM patients with DR compared to T2DM controls (26.9% vs. 17.9%, P = 0.011). Similarly, the frequency of the C allele was higher in cases than in controls (48% vs. 39%; P = 0.001). Additionally, this difference was significant under the recessive (P = 0.017), additive (P = 0.004), and dominant (P = 0.016) genetic models.
Table 2: Genotype and allele frequencies of the ELMO1 rs741301 SNP in T2DM patients categorized according to the presence of DR
After adjustment for age, gender, age at DM diagnosis, HDL cholesterol levels, and the presence of DKD, the C/C genotype of the rs741301 SNP was associated with increased risk of DR (OR = 1.805, 95%CI 1.101–2.961; P = 0.019). This association was also observed under the additive and dominant genetic models adjusting for the same covariates (additive model: OR = 1.818, 95%CI 1.099-3.007; P = 0.020; dominant model: OR = 1.597, 95%CI 1.089-2.343; P = 0.017).
Interestingly, when we stratified patients according to the DR severity, the frequency of the C/C genotype was 17.9% in the control group, 25.3% in the NPDR group, and 29.1% in the PDR group (P = 0.042). No difference was found when comparing the frequency of the C/C genotype between patients with NPDR and patients with PDR (25.3% vs. 29.1%, respectively; P = 0.711).
DISCUSSION
This study aimed to investigate the frequency of the ELMO1 rs741301 SNP in patients with T2DM stratified by the presence of DR. We demonstrated, for the first time, an association between the rs741301 C allele and an increased risk of DR in patients with T2DM from Southern Brazil. The association between the ELMO1 rs741301 SNP and the risk of DR in patients with T2DM is plausible, with a probable relation to DR by the gene’s involvement in angiogenesis and oxidative stress pathways (^26^).
Supporting this, an experimental study using zebrafish demonstrated a decrease in vascular formation in the retina of Elmo1-/- zebrafish (^25^). Moreover, an observed increase in vessel thickness in larval hyaloids further suggests an impact of Elmo1 on vessel structure, broadening its regulatory capacity in the vasculature (^25^). Therefore, we hypothesized that the rs741301 SNP in the ELMO1 gene may alter ELMO1 expression and consequently affect its function in vascular development.
Although no study to date has reported the involvement of ELMO1 in the development of DR or analyzed the SNP in patients with DR, several studies have reported an association between the rs741301 SNP in ELMO1 gene and an increased risk of DKD. In this context, it is important to highlight that DKD and DR share several common pathways, including the accumulation of oxidative stress due to chronic hyperglycemia, attributed to five main mechanisms: increased formation of advanced glycation end- products; elevated expression of the receptor for advanced glycation end-products; activation of protein kinase C isoforms; increased glucose flux in the polyol pathway; and upregulation of the hexosamine pathway (^34^). Additionally, Fang and cols. (^35^) conducted a two-sample mendelian randomization study from the perspective of genetics to assess the causal relation between DR and DKD. Data from twenty polymorphisms associated with DR from the FinnGen Consortium were tested regarding their associations with DKD. The authors showed positive associations of 20 genetically predicted DR polymorphisms with risk of DKD. Thus, polymorphisms associated with DKD may also be associated with DR.
Regarding the association of the rs741301 SNP in ELMO1 and DKD, Bayoumy and cols. (^17^) found that the C/C genotype of this SNP was associated with a higher risk of DKD (OR = 2.7, 95%CI 1.4- 5.3; P = 0.016) in a study involving 400 Egyptian patients with DM, half of whom had DKD. Similarly, in Chinese patients with T2DM, the presence of the C allele of the rs741301 SNP was associated with an increased risk of DKD (OR = 1.75, 95%CI 1.19-2.28; P < 0.001) (^20^). This finding was consistent with a study conducted in the Iranian population, in which the presence of the C allele was associated with an elevated risk of DKD (OR = 2.5, 95%CI 1.2-5.4; P = 0.010) (^22^). In contrast, Bodhini and cols. (^18^) reported the association of the T/T genotype with an increased risk of DKD (OR = 1.48, 95%CI 1.02-2.55; P = 0.035) in patients with T2DM from a South Indian population. However, no association between the rs741301 SNP and DKD was found in studies conducted in Polish (^21^), Chinese (^23^), and Egyptian (^19^) populations.
Despite inconclusive results, ELMO1 appears to play a role in DKD pathogenesis. Hathaway and cols. (^24^) demonstrated that the severity of renal fibrosis and urinary albumin excretion levels correlated with Elmo1 expression values in Akita mice with genetically induced different levels of this gene. Additionally, higher expression of Elmo1 correspondingly led to an increase in the levels of reactive oxygen species, indicating the potential involvement of this gene in renal damage by increased oxidative stress (^24^). Moreover, ELMO1 was also described as a promotor of angiogenesis and early vascular development in zebrafish (^25^).
While our results contribute to a better understanding of the involvement of genetic polymorphisms in the pathogenesis of DR, a few limitations should be considered when interpreting our findings. First, there is the possibility of population stratification bias in our sample despite our focus on white participants and recruitment from the same hospitals for both cases and controls, which aimed to minimize the risk of false-positive/negative associations due to this bias. Second, our study represents the first demonstration of an association between the ELMO1 rs741301 SNP and the risk of DR, yet we did not conduct a replication of this observed association in another Brazilian sample. Third, there is a lack of information regarding how the rs741301 SNP affects ELMO1 expression and its functional role on DR susceptibility. Therefore, additional genetic studies are warranted to confirm the association between the rs741301 SNP in the ELMO1 and the risk of DR in different ethnicities and populations. Moreover, functional studies are essential for a deeper understanding of how the rs741301 SNP influences ELMO1 expression and activity.
In conclusion, this study provides the first evidence of an association between the C allele of the rs741301 SNP in the ELMO1 gene and the risk of DR. This association appears to be plausible given the known involvement of ELMO1 in vascular formation, angiogenesis, and the accumulation of reactive oxygen species. Further studies are needed to validate these findings in other populations.
Acknowledgments: this study was partially financially supported by Conselho Nacional Desenvolvimento Científico e Tecnológico (CNPq), Financiamento e Incentivo à Pesquisa (Fipe) at Hospital de Clínicas de Porto Alegre (number 2022-0383), Fundação de Amparo à Pesquisa do Estado do Rio Grande do Sul (Fapergs; number 1928-2551/13-2), and Coordenação de Aperfeiçoamento de Pessoal de Nível Superior (Capes). Cristine Dieter, Daisy Crispim, Luciane Moretto, and Luís Henrique Canani received scholarships from CNPq, while Eliandra Girardi received a scholarship from Fapergs.
Disclosure: no potential conflict of interest relevant to this article was reported.
The reference list from the paper itself. Each links out to its DOI / PubMed record.
- 1Sun H Saeedi P Karuranga S Pinkepank M Ogurtsova K Duncan BB IDF Diabetes Atlas: Global, regional and country-level diabetes prevalence estimates for 2021 and projections for 2045.Diabetes Res Clin Pract 20220118310911910911910.1016/j.diabres.2021.10911934879977 PMC 11057359 · doi ↗ · pubmed ↗
- 2Wong TY Cheung CM Larsen M Sharma S Simo R. Diabetic retinopathy.Nat Rev Dis Primers 201603172160121601210.1038/nrdp.2016.1227159554 · doi ↗ · pubmed ↗
- 3Bhatwadekar AD Shughoury A Belamkar A Ciulla TA. Genetics of Diabetic Retinopathy, a Leading Cause of Irreversible Blindness in the Industrialized World.Genes (Basel)202107311281200120010.3390/genes 1208120034440374 PMC 8394456 · doi ↗ · pubmed ↗
- 4Costa AR Dieter C Canani LH Assmann TS Crispim D. The rs 1800469 T/T and rs 1800470 C/C genotypes of the TGFB 1 gene confer protection against diabetic retinopathy in a Southern Brazilian population.Genet Mol Biol 2023077463 e 2022024710.1590/1678-4685-GMB-2022-024737418683 PMC 10328150 · doi ↗ · pubmed ↗
- 5Dieter C Lemos NE de Faria Correa NR Assmann TS Pellenz FM Canani LH Polymorphisms in TIE 2 and ANGPT-1 genes are associated with protection against diabetic retinopathy in a Brazilian population.Arch Endocrinol Metab 20230525675 e 00062410.20945/2359-399700000062437249455 PMC 10665047 · doi ↗ · pubmed ↗
- 6Brondani LA Crispim D Pisco J Guimaraes JA Berger M. The G Allele of the rs 12050217 Polymorphism in the BDKRB 1 Gene Is Associated with Protection for Diabetic Retinopathy.Curr Eye Res 20190944999499910.1080/02713683.2019.161017831017477 · doi ↗ · pubmed ↗
- 7Dieter C Lemos NE de Faria Correa NR Costa AR Canani LH Crispim D The rs 2442598 polymorphism in the ANGPT-2 gene is associated with risk for diabetic retinopathy in patients with type 1 diabetes mellitus in a Brazilian population.Arch Endocrinol Metab 2021112465679480010.20945/2359-399700000041734762787 PMC 10065396 · doi ↗ · pubmed ↗
- 8Valiatti FB Crispim D Benfica C Valiatti BB Kramer CK Canani LH. [The role of vascular endothelial growth factor in angiogenesis and diabetic retinopathy].Arq Bras Endocrinol Metabol 20110355210611310.1590/S 0004-2730201100020000221584427 · doi ↗ · pubmed ↗
